Articles tagged with: ENMD-2076
NewsFlash »
Celgene Seeks Expanded Approval For Revlimid In Europe – The pharmaceutical company Celgene announced on Tuesday that it is seeking expanded approval for Revlimid (lenalidomide) as treatment for multiple myeloma in Europe. The European Medicines Agency (EMA) will review approval of Revlimid for maintenance therapy of newly diagnosed myeloma patients who have not progressed after initial therapy with melphalan (Alkeran), prednisone, and Revlimid or after autologous stem cell transplantation. Currently, Revlimid is approved in combination with dexamethasone for the treatment of patients who have received at least one prior therapy. For more information, please see the Celgene press release.
ENMD-2076 Is Safe In Relapsed/Refractory Multiple Myeloma (ASH 2010) – The investigational drug ENMD-2076, which is being developed by the pharmaceutical company EntreMed, is safe in relapsed / refractory multiple myeloma patients, according to the interim Phase 1 trial results presented at the 2010 Meeting of the American Society of Hematology (ASH). Researchers tested four different dose levels (150 mg to 400 mg) in 28-day cycles. They observed progression of disease for all patients receiving the minimum dose of 150 mg. Patients receiving a dose of 300 mg achieved stable disease with reductions in serum M-protein. Researchers did not observe any dose-limiting side effects. Most side effects were mild to moderate and included nausea, diarrhea, and fatigue. The optimal dosage has not yet been determined as the trial is still ongoing. For more information, please see abstract 1957 on the ASH annual meeting website and the clinical trial description.
Daratumumab Emerges As Potential Treatment In CD38-Positive Multiple Myeloma – Preclinical results showed that the experimental drug daratumumab is highly effective at killing cancerous cells that produce the CD38 molecule. The Danish biotechnology company Genmab is currently developing daratumumab for treatment of CD38-positive multiple myeloma tumors. Researchers initially tested a broad array of CD38 antibodies against more than 10 primary tumors from myeloma patients, and daratumumab was found to be the most effective at executing the immune system killing mechanisms. Genmab is currently conducting a Phase 1/2 study to determine the safety and optimal dosage of daratumumab. For more information, please see the study in the Journal of Immunology (abstract) and the clinical trial description.
PBOX-15 Induces Cell Death In Multiple Myeloma Cells – Preclinical results demonstrated that the experimental drug compound PBOX-15 (1,5-benzoxazepine-15), discovered by Irish clinical scientists, is a promising treatment for multiple myeloma. Researchers found that PBOX-15 induced cell death in four different lines of multiple myeloma cells. In two of the cell lines, PBOX-15 increased the number of death receptor genes to stimulate cell death. For more information, please see the study in the British Journal of Cancer (abstract).
NewsFlash »
Onyx Pharmaceuticals Initiates Phase 3 Myeloma Trial Of Carfilzomib – Onyx Pharmaceuticals on Wednesday announced the start of enrollment for an international Phase 3 trial of carfilzomib in relapsed/refractory multiple myeloma patients. The trial will enroll 700 patients and will test carfilzomib in combination with Revlimid (lenalidomide) and low-dose dexamethasone (Decadron) versus Revlimid and low-dose dexamethasone without carfilzomib. Carfilzomib is a proteasome inhibitor that prevents the growth and spread of myeloma cells by interrupting their protein-related cellular processes. For more information, please see the Onyx Pharmaceuticals press release and the clinical trial description.
EntreMed’s ENMD-2076 Shows Anti-Myeloma Activity – EntreMed announced last week that its new cancer compound ENMD-2076 showed significant anti-myeloma activity in pre-clinical studies. EntreMed has already launched a Phase 1 study in multiple myeloma patients. ENMD-2076 prevents the growth and spread of myeloma cells by interfering with cell division. For more information, please see the EntreMed press release and the clinical trial description.
IMF Will Hold Myeloma Patient & Family Seminar – The International Myeloma Foundation (IMF) will be holding a seminar for myeloma patients and their families August 13 to 14 in Philadelphia, PA. Myeloma experts Dr. Brian Durie and Dr. Robert Kyle are among the speakers scheduled to present during Saturday’s general session. The cost for the seminar is $60 per person. For more information or to register, please visit the IMF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.